Desenvolvimento e aplicação de carreadores lipídicos nanoestruturados contendo finasterida para o tratamento de alopecia androgenética
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
Beyond its aesthetic importance, hair distinguishes the individual and can influence
social acceptance. Under certain circumstances, the normal hair growth process is impaired
by a very common physiological disorder called androgenetic alopecia (AGA). The hair loss
is the consequence of an increased expression of 5α-reductase enzyme that converts
testosterone into dihydrotestosterone. To treat AGA, finasteride, an antiandrogenic steroid,
can be used in two forms: oral or topical. However, for both forms, side effects such as
irritation, decreased libido, contact dermatitis and mood changes have been reported. The
use of nanocarriers as a vehicle for drugs can reduce such side effects by reducing the need
for high doses or concentrations and frequent reapplications. The objective of this study is
to develop nanostructured lipid nanoparticles containing finasteride (NLC-FNS07) for
androgenetic alopecia treatment. As a preview result, it’s showed here the construction of
the nanoparticles with natural origin lipids adjusted to release on defined temperature and
stabilized with copolimers in block. Such nanoparticles were built with natural origin lipids
adjusted to release the drug in specific temperature and stabilized with block copolymers.
After preparation using ultrasonic irradiation, the lipid nanocarriers produced exhibited
hydrodynamic diameter with average size of 119.56 ± 1.07 nm and polydispersity index of
0.186. Due to the hydrophobic characteristics of the drug, the encapsulation efficiency
reached values close to 100% after HPLC quantification. The suspension kept its
characteristics through 30 days, showing good stability. In addition, the nanostructures
reduced the finasteride cytotoxicity for fibroblasts and keratinocytes cells. Subsequently,
permeation, controlled release and in vivo efficiency tests were carried out. NLC-FNS07
improved the drug stability and skin permeation, while reducing skin irritation and inflammation,
without systemic absorption. Finally, it showed efficient hair restoration in vivo, and remained in the
epidermis, including the bulbs, suggesting safety for topical administration. The promising efficacy
of our novel NLC-FNS07 in AGA treatment designates it as a good candidate for therapeutic
applications.
Description
Keywords
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

